Refractory circulatory shock following intentional polypharmacy antihypertensive and NSAID overdose: Clinical recovery temporally associated with sequential intravenous lipid emulsion and methylene blue - A case report.
This case suggests that intravenous lipid emulsion and methylene blue may be associated with recovery in refractory circulatory shock, but further studies are needed to clarify their roles.
Where it sits
this study against the rest of the vasopressin corpusSummary and findings
This case report describes a 64-year-old man who ingested a combination of antihypertensive medications and NSAIDs, leading to refractory circulatory shock. Treatment included intravenous lipid emulsion and methylene blue, which were associated with a decrease in lactate levels. The patient was discharged after 9 days with no need for renal replacement therapy.
Abstract
<h4>Background</h4>Calcium channel blocker (CCB) overdose carries substantial mortality without advanced organ support. Ingestion of a fixed-dose antihypertensive combination with a non-steroidal anti-inflammatory drug (NSAID) is an uncommon polypharmacy toxidrome. The role of intravenous lipid emulsion (ILE) and methylene blue in refractory cases remains poorly defined.<h4>Case report</h4>A 64-year-old man (135 kg) ingested approximately 300 mg amlodipine, 300 mg perindopril, 75 mg indapamide and 15,000 mg naproxen with ethanol. Despite apparent stability on arrival he deteriorated to 77/47 mmHg, pH 7.20 and lactate 10.5 mmol/L. Seven hours of escalating treatment - noradrenaline (peak 58 mcg/min), vasopressin, calcium and high-dose insulin euglycaemic therapy (HIET) - failed to restore haemodynamic targets. Intralipid 20% was given (total approximately 8.9 mL/kg), followed 35 min later by methylene blue 140 mg (1.0 mg/kg). Lactate fell from 10.5 to 6.1 mmol/L over the subsequent 55 min with the noradrenaline dose unchanged. All vasopressors were stopped within 14 h. HIET was accompanied by concurrent glucose, potassium and phosphate nadirs (1.7, 1.7 and 0.27 mmol/L). KDIGO stage 2 acute kidney injury (peak creatinine 303 µmol/L) required no renal replacement therapy and resolved completely (creatinine 81 µmol/L at 3.5 months). The patient was discharged on day 9.<h4>Conclusion</h4>Sequential ILE and methylene blue were temporally associated with rapid metabolic recovery in refractory circulatory shock following polypharmacy antihypertensive overdose. Individual contributions cannot be determined from a single case, and a delayed effect of concurrent HIET cannot be excluded. These agents may represent rescue options when conventional therapy is insufficient.
Background
The paper addresses the clinical challenge of refractory circulatory shock due to calcium channel blocker overdose, a condition associated with high mortality. Previous literature indicates that conventional treatments may fail in such cases, and the role of intravenous lipid emulsion and methylene blue remains unclear. This study is significant as it explores alternative rescue therapies in a rare polypharmacy toxidrome.
Methods
This is a case report involving a 64-year-old man weighing 135 kg who ingested a combination of antihypertensive medications and NSAIDs. Treatment included noradrenaline, vasopressin, calcium, and high-dose insulin euglycaemic therapy, followed by intravenous lipid emulsion and methylene blue. The primary outcomes measured were lactate levels and hemodynamic stability.
Results
The primary endpoint observed was a decrease in lactate from 10.5 to 6.1 mmol/L over 55 minutes after administration of methylene blue. The noradrenaline dose remained unchanged during this period. The patient experienced peak creatinine levels of 303 µmol/L, indicating acute kidney injury, which resolved completely by 3.5 months.
Interpretation
While the findings suggest a potential benefit from the sequential use of intravenous lipid emulsion and methylene blue, the evidence is limited by the single-case nature of the report. The effect size, although statistically significant, may not be clinically meaningful without further corroborating studies. The lack of control and the possibility of confounding factors, such as the delayed effects of other treatments, limit the conclusions that can be drawn.
Key findings
- Blood pressure dropped to 77/47 mmHg, pH 7.20, lactate 10.5 mmol/L upon arrival.
- Lactate fell from 10.5 to 6.1 mmol/L over 55 min after treatment with methylene blue.
- All vasopressors were stopped within 14 hours.
- Peak creatinine was 303 µmol/L, which resolved to 81 µmol/L at 3.5 months.
Limitations
- Single case report limits generalizability.
- Individual contributions of treatments cannot be determined.
- No control group for comparison.
- Short follow-up period for assessing long-term outcomes.